Release Date: May 09, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Dr Reddy's Laboratories Ltd (NYSE:RDY) achieved record high revenue exceeding $3.8 billion and crossed the $1 billion threshold in EBITDA for the first time. The company reported a year-over-year revenue growth of 17% for the full year, driven by strategic acquisitions and contributions from its generic portfolio. EBITDA margins remained resilient, exceeding 29% for the quarter and closing the full year at over 28%. The company successfully integrated its newly acquired nicotine replacement therapy business in the UK and is on track to complete integration in the Nordics. Dr Reddy's Laboratories Ltd (NYSE:RDY) maintained a net cash surplus balance of 2,454 crores post-acquisition payouts, enhancing financial flexibility for future growth initiatives.

Negative Points

The consolidated gross profit margin for the fourth quarter declined by 300 basis points year-over-year, primarily due to reduced manufacturing overhead leverage. Selling and general administrative expenses increased by 22% year-over-year, driven by the acquired consumer healthcare business and higher logistics costs. The effective tax rate for the full year was higher than the previous year, mainly due to the reversal of previously recognized deferred tax assets. The company faced impairment losses of 77 crores in Q4 and 169 crores for the full year, related to certain product-related intangibles due to adverse market conditions. There was a sequential decline of 30% in the emerging markets generic business revenue for Q4, despite a year-over-year growth of 16%.

Q & A Highlights

Warning! GuruFocus has detected 5 Warning Signs with GSBD.

Q: What is Dr. Reddy's strategy regarding potential tariffs on generics, and how will it affect the company's operations given it doesn't have manufacturing in the US? A: (Unidentified_4) We are preparing for various scenarios and closely monitoring developments. Our main focus is ensuring supply sustainability by working with customers on inventory needs. We are not planning specific actions to build a US manufacturing footprint unless the right opportunity arises. The impact of tariffs will depend on whether they apply to APIs or finished products, and we will adjust our strategy accordingly.

Q: How flexible is Dr. Reddy's cost base, particularly in R&D and SG&A, to maintain margins as revenue grows? A: (Unidentified_3) We expect to maintain R&D and SG&A expenses at similar levels, with R&D at around 8% of sales. Our strategy is to grow sales faster than expenses, using productivity measures rather than cost cuts. We aim to achieve double-digit growth while maintaining margins.

Story Continues

Q: Can you explain the significant changes in gross margin on a quarter-over-quarter basis? A: (Unidentified_3) The decline in gross margin was due to one-off costs, including severance and lower out-licensing income compared to the previous quarter. These factors contributed to a 300 basis point decrease in gross margin, which we expect to normalize in future quarters.

Q: What is the outlook for the generic semaglutide market in Canada and other emerging markets? A: (Unidentified_4) Canada is a key market with exclusivity ending in January 2026. The market is growing, with a current size of approximately $1.8 billion. We anticipate significant volume growth as prices decrease, and we plan to be among the first to launch in Canada and other markets as IP landscapes allow.

Q: How does Dr. Reddy's plan to address potential regulatory changes in the US, such as increased inspections? A: (Unidentified_4) Our facilities are prepared for unannounced inspections, which have been part of US guidelines for years. We are ready to comply with any regulatory changes and do not anticipate significant impacts on our operations.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments